Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 12, 2007

Array BioPharma Earns Milestone from AstraZeneca

  • AstraZeneca dosed the first patient in a Phase I trial of Array BioPharma’s anticancer candidate. The milestone triggered a $2-million payment to Array BioPharma.

    ARRY-704 (AZD8330) is potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. ARRY-704 has shown tumor suppressive activity in multiple preclinical models of human cancer, including melanoma, pancreatic, colon, lung, and breast cancers, according to Array BioPharma.

    In December 2003, Array partnered the oncology portion of its MEK program for co-development and commercialization with AstraZeneca. The collaboration included R&D of additional clinical candidates, which resulted in the selection of ARRY-704 in December 2005.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.